Yun Kyeong Ho, Jeong Myung Ho, Kim Kye Hun, Hong Young Joon, Park Hyung Wook, Kim Ju Han, Ahn Young Keun, Cho Jeong Gwan, Park Jong Chun, Kim Nam Ho, Oh Seok Kyu, Jeong Jin Won, Kang Jung Chaee
The Heart Center of Chonnam National University Hospital, Dong-gu, Gwangju, Korea.
J Korean Med Sci. 2006 Apr;21(2):212-6. doi: 10.3346/jkms.2006.21.2.212.
Insulin resistance is an important risk factor for coronary artery disease. However, there has been no data regarding its clinical effect on the outcomes of percutaneous coronary intervention (PCI) in non-diabetic patients. We analyzed 98 non-diabetic consecutive patients (59+/-11.5 yr, male:female=63:35) who underwent elective coronary angiography. The patients were divided into two groups: Group I (n=71; the value of HOMA-IR [homeostasis model assessment of insulin resistance] <2.6) and Group II (n=27; the value of HOMA-IR > or = 2.6). In-hospital and 30-day major adverse cardiac events (MACE) were compared between the two groups. The concentrations of fasting insulin and triglyceride were significantly higher in Group II than in Group I. Significant correlations were observed between the value of HOMA-IR and body mass index (r=0.489, p<0.001), levels of total cholesterol (r=0.204, p=0.045), triglyceride (r=0.334, p=0.001) and apolipoprotein B (r=0.212, p=0.038). PCI was performed in 59 patients (60.2%). In-hospital and 30-day MACE were higher in Group II than Group I (2.4% vs. 27.8%, p=0.008; 2.4% vs. 27.8%, p=0.008). Multivariate analysis revealed that the value of HOMA-IR > or = 2.6 was an independent predictor of MACE. Increased HOMA-IR level is an important prognostic indicator in non-diabetic patients underwent PCI.
胰岛素抵抗是冠状动脉疾病的一个重要危险因素。然而,尚无关于其对非糖尿病患者经皮冠状动脉介入治疗(PCI)结局的临床影响的数据。我们分析了98例连续接受择期冠状动脉造影的非糖尿病患者(年龄59±11.5岁,男∶女 = 63∶35)。患者被分为两组:I组(n = 71;胰岛素抵抗稳态模型评估值[HOMA-IR]<2.6)和II组(n = 27;HOMA-IR值≥2.6)。比较两组患者的院内及30天主要不良心脏事件(MACE)。II组空腹胰岛素和甘油三酯浓度显著高于I组。观察到HOMA-IR值与体重指数(r = 0.489,p<0.001)、总胆固醇水平(r = 0.204,p = 0.045)、甘油三酯(r = 0.334,p = 0.001)及载脂蛋白B(r = 0.212,p = 0.038)之间存在显著相关性。59例患者(60.2%)接受了PCI。II组的院内及30天MACE高于I组(2.4% 对27.8%,p = 0.008;2.4% 对27.8%,p = 0.008)。多因素分析显示,HOMA-IR值≥2.6是MACE的独立预测因素。HOMA-IR水平升高是接受PCI的非糖尿病患者的重要预后指标。